Display options
Cite
Santiago D, Mangas-Sanjuan V, Melin K, et al. Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics. 2020;12(12)doi: 10.3390/pharmaceutics12121226.
Santiago, D., Mangas-Sanjuan, V., Melin, K., Duconge, J., Zhao, W., & Venkataramanan, R. (2020). Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics, 12(12), . https://doi.org/10.3390/pharmaceutics12121226
Santiago, Darlene, et al. "Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico." Pharmaceutics vol. 12,12 (2020). doi: https://doi.org/10.3390/pharmaceutics12121226
Santiago D, Mangas-Sanjuan V, Melin K, Duconge J, Zhao W, Venkataramanan R. Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics. 2020 Dec 18;12(12). doi: 10.3390/pharmaceutics12121226. PMID: 33352843; PMCID: PMC7766849.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2020 Dec 18;12(12). doi: 10.3390/pharmaceutics12121226.

Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico.

Pharmaceutics

Darlene Santiago, Victor Mangas-Sanjuan, Kyle Melin, Jorge Duconge, Wenchen Zhao, Raman Venkataramanan

Affiliations

  1. Pharmaceutical Sciences Department, School of Pharmacy, University of Puerto Rico, 00936-5067 San Juan, Puerto Rico.
  2. Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain.
  3. Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia, University of Valencia, 46100 Valencia, Spain.
  4. Pharmacy Practice Department, School of Pharmacy, University of Puerto Rico, 00936-5067 San Juan, Puerto Rico.
  5. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  6. Department of Pathology, MWRI, UPCI, MIRM, Thomas Starzl Transplantation Institute, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.

PMID: 33352843 PMCID: PMC7766849 DOI: 10.3390/pharmaceutics12121226

Abstract

BACKGROUND: The aim of this analysis was to characterize the pharmacokinetics (PK) of sublingual buprenorphine (BUP) and its metabolites (buprenorphine glucuronide; BUP-g, norbuprenorphine; Nor-BUP, and norbuprenorphine glucuronide; Nor-BUP-g) in opioid use disorder (OUD) patients in Puerto Rico (PR) as a first step of evidence-based BUP dosing strategies in this population.

METHODS: BUP and metabolites concentrations were measured from 0 to 8 h after the administration of sublingual buprenorphine/naloxone films in 12 stable OUD subjects.

RESULTS: PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (

CONCLUSIONS: Although limited in sampling time and number of recruited subjects, this study presents specific BUP PK characteristics that evidenced the need for additional PK studies and subsequent modeling of the data for the development of evidence-based dosing approaches in Puerto Rico.

Keywords: Puerto Ricans; Suboxone; buprenorphine/naloxone sublingual film; compartmental modeling; opioid use disorder (OUD); pharmacokinetics; popPK; population pharmacokinetics

References

  1. Br J Clin Pharmacol. 1982 May;13(5):665-73 - PubMed
  2. Clin Pharmacokinet. 2014 Sep;53(9):813-24 - PubMed
  3. Clin Pharmacokinet. 2004;43(5):329-40 - PubMed
  4. Am J Prev Med. 2018 May;54(5):652-660 - PubMed
  5. Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S39-47 - PubMed
  6. Pain Med. 2018 Oct 1;19(10):1988-1996 - PubMed
  7. Br J Clin Pharmacol. 2017 Nov;83(11):2458-2473 - PubMed
  8. Clin Infect Dis. 2012 Feb 1;54(3):414-23 - PubMed
  9. Drug Alcohol Depend. 2014 Nov 1;144:1-11 - PubMed
  10. J Anal Toxicol. 1996 Oct;20(6):369-78 - PubMed
  11. Ther Drug Monit. 2020 Apr;42(2):264-270 - PubMed
  12. Comput Methods Programs Biomed. 2005 Sep;79(3):241-57 - PubMed
  13. Drug Alcohol Depend. 2006 Mar 15;82(1):25-31 - PubMed
  14. Drug Alcohol Depend. 2003 Oct 24;72(1):75-83 - PubMed
  15. Anesthesiology. 2006 Jun;104(6):1232-42 - PubMed
  16. Drugs R D. 2019 Sep;19(3):255-265 - PubMed
  17. Neuropsychopharmacology. 2003 Nov;28(11):2000-9 - PubMed
  18. Pharmacotherapy. 2015 Jul;35(7):670-80 - PubMed
  19. J Clin Pharmacol. 2006 Feb;46(2):179-92 - PubMed
  20. J Natl Med Assoc. 2012 Jul-Aug;104(7-8):342-50 - PubMed
  21. AAPS J. 2011 Jun;13(2):143-51 - PubMed
  22. Clin Pharmacol Ther. 2007 Jan;81(1):50-8 - PubMed
  23. PLoS One. 2017 Apr 26;12(4):e0176443 - PubMed
  24. Drug Metab Dispos. 1984 Sep-Oct;12(5):577-81 - PubMed
  25. Drug Alcohol Depend. 2011 Nov 1;118(2-3):479-83 - PubMed
  26. CMAJ. 2018 Mar 5;190(9):E247-E257 - PubMed
  27. Eur J Pharm Sci. 2018 Sep 15;122:125-133 - PubMed
  28. Biol Psychiatry. 2007 Jan 1;61(1):101-10 - PubMed
  29. Am J Obstet Gynecol. 2017 Jan;216(1):64.e1-64.e7 - PubMed
  30. Drug Alcohol Depend. 1999 Aug 2;56(1):55-60 - PubMed

Publication Types

Grant support